PHARMACOLOGICAL CORRECTION OF COGNITIVE DISORDERS IN EXPERIMENTAL NEURODEGENERATION CAUSED BY 2 TYPE DIABETES MELLITUS*

Authors

  • Kmet O. G. Higher State Educational Establishment of Ukraine «Bukovinian State Medical University», Chernivtsi, Ukraine
  • Filipets N. D. Higher State Educational Establishment of Ukraine «Bukovinian State Medical University», Chernivtsi, Ukraine
  • Kmet T. I. Higher State Educational Establishment of Ukraine «Bukovinian State Medical University», Chernivtsi, Ukraine
  • Hrachova T. I. Higher State Educational Establishment of Ukraine «Bukovinian State Medical University», Chernivtsi, Ukraine
  • Vepriuk Y. M. Higher State Educational Establishment of Ukraine «Bukovinian State Medical University», Chernivtsi, Ukraine
  • Vlasova K. V. Higher State Educational Establishment of Ukraine «Bukovinian State Medical University», Chernivtsi, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2019.4.07

Keywords:

type 2 diabetes mellitus, neurodegeneration, carbacetam, enalapril, cognitive ability of rats.

Abstract

A progressive increase of complications of type 2 DM makes the problem very important for clinical and
fundamental medicine. In particular, neurodegenerative processes in case of type 2 DM aggravate the course
of the disease, change a usual life rhythm, and are a valuable cause of high rates of disability and lethality.
Deterioration of cognitive functions is one of the main complications of diabetes. In certain literary sources
inhibitors of angiotensin-transforming enzyme are considered as the means to prevent and treat complications
of diabetes mellitus. Their role as modulators of gama-aminobutyric acid with development of central diabetic
neurodegeneration is not completely determined yet.
Therefore, the objective of the study is to assess efficacy of pharmacological correction of cognitive disorders
by carbacetam, a GABA modulator, and enalapril, a RAS blocker, in case of experimental neurodegeneration
caused by type 2 DM.
Changes of the cognitive functions under carbacetam and enalapril effect in nonlinear laboratory albino
male rats with neural degeneration under conditions of type 2 diabetes mellitus simulated by streptozotocin and
high fat diet are studied. The cognitive ability was assessed by behavioral reactions of rats in the tests «open
field» and «the conditional reflex reaction of passive avoidance» by Butler formula.
Behavior of rats with type 2 diabetes mellitus after administration of carbacetam and enalapril showed of
cognitive functions in the groups. At the same time, carbacetam was found to possess better correcting effect on
adaptation, cognitive reactions and anti-amnestic activity, while enalapril improved emotional condition of the
rats mostly. Analysis of anti-amnestic properties found higher values of the parameters on the 14th day than on
the 1st day of correction, which is indicative of the efficacy of a course administration of carbacetam and enalapril under conditions of neural degeneration stipulated by type 2 DM.

References

Vinod N. Gerontol Geriatric Stud. 2018; 3(2): 1-14. doi: http://doi.org/10.31031/GGS.2018.03.000556.

Yin F, Sancheti H, Patil I, Cadenas E. Free Radic Biol Med. 2016; 100: 108-122. doi: http://doi.org/10.1016/j.freeradbiomed. 2016.04.200.

Kalchenko VI, Wovk MV, Rodik RV, Yarosh AK. Pharmacol Drug Toxicol. 2016; 6(51): 21-31.

Poltorak VV, Gorshuns’ka MJu, Krasova NS. Mezhdunar Jendokrinol Zhurn. 2014; 5(6): 15-21.

Hertz L. Front Endocrinol. 2013; 4(59): 1-16. doi: http://doi.org/10. 3389/fendo.2013.00059.

Panov A, Orynbayeva Z, Vavilin V, Lyakhovich V. Bio­med Res Int. 2014; 2014: 472459. doi: http://doi.org/10.1155/2014/ 472459.

Li Y, Sun H, Chen Z, at al. Front Aging Neurosci 2016; 8(31): 1-12. doi: http://doi.org/10.3389/fnagi.2016.00031.

Kozak DV. Shpytal’na hirurgija. Zhurn im. L. Ja. Koval’chuka. 2014; 1(65): 40-42.

Huang X, Lu G, Li G, et al. Front Neurosci. 2017; 11: 11. doi: http://doi.org/10.3389/fnins.2017.00359.

Jawaid T, Jahan S, Kamal MJ. Adv Pharm Technol Res. 2015; 6(3): 130-135. doi: http://doi.org/ 10.4103/2231-4040.161514.

Rybak VA, Maloshtan LM, Poltorak VV, Krasova NS. Pharmacol Drug Toxicol 2015; (42):76-81.

Apryatin SA, Shipelin VA, Trusov NV, et al. Physiol Rep. 2019; 7(4): 13987. doi: http://doi.org/10.14814/phy2.13987.

Martinez-Dнaz JA, Garcia LI, Hernandez ME, ArandaAbreu GE. Neurologia. 2015; 30(7): 407-415. doi. http://doi.org/ org/ 0.1016/j.nrleng.2014.03.003.

Kmet OG, Ziablitsev SV, Filipets ND, et al. Arch Balkan Med Union. 2019; 54(1): 124-129. doi. http://doi.org/ org/10.31688/ABMU. 2019.54.1.17.

Deiko RD, Strigol SJ, Kolobov OO, Bezditko NV. Pharmacol Drug Toxicol. 2015; 6(46): 19-27.

Trujeque-Ramos S, Castillo-Rolуn D, Galarraga E, et al. Front Neurosci. 2018. 1-15. doi: http://doi.org/ 10.3389/fnins.2018.00345.

Cheng Zhou, Jin Liu, Xiang-Dong Chen. World J Crit Care Med. 2012; 1(3): 80-93. doi: http://doi.org/10.5492/wjccm.v1.i3.80.

Ramsey CP, Tansey MG. Exp Neurol. 2014; 256: 126132. doi: http://doi.org/10.1016/j.expneurol.2013.05.014.

Almeida-Santos F, Kangussu AM, Moreira FA, et al. Protein Peptide Lett. 2017; 24(9): 841-853. doi: http://doi.org/10.2174/ 0929866524666170822120258.

Luppi M, Hitrec T, Di Cristoforo A, et al. Front Neuroanat. 2019; 13(57): 1-doi: http://doi.org/10.3389/fnana.2019.00057.

Downloads

Published

2019-11-11

How to Cite

Kmet, O. G., Filipets, N. D., Kmet, T. I., Hrachova, T. I., Vepriuk, Y. M., & Vlasova, K. V. (2019). PHARMACOLOGICAL CORRECTION OF COGNITIVE DISORDERS IN EXPERIMENTAL NEURODEGENERATION CAUSED BY 2 TYPE DIABETES MELLITUS*. Problems of Endocrine Pathology, 70(4), 52-59. https://doi.org/10.21856/j-PEP.2019.4.07

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)